New drug combo takes on tough cancers in early trial
NCT ID NCT06764771
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing an experimental drug called BMS-986488, alone or combined with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 437 adults with certain cancers like kidney, lung, or colorectal cancer are taking part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BMS-986488 (an experimental drug), sometimes combined with adagrasib, cetuximab, or nivolumab
What this could lead to
If it works, this could point toward a new treatment option for certain advanced cancers that are hard to treat.
What could go wrong
This is an early Phase 1 trial focused on safety, not yet on effectiveness. It is small and may not lead to a proven therapy. Side effects are unknown and could be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
John Theurer Cancer Center at Hackensack University Medical Center
RECRUITINGHackensack, New Jersey, 07601, United States
Contact Phone: •••-•••-••••
-
Local Institution - 0015
NOT_YET_RECRUITINGMontreal, Quebec, H2X 0A9, Canada
Contact
-
Local Institution - 0016
ACTIVE_NOT_RECRUITINGQuébec, Quebec, G1J 1Z4, Canada
-
Local Institution - 0020
ACTIVE_NOT_RECRUITINGAllentown, Pennsylvania, 18103, United States
-
Local Institution - 0025
WITHDRAWNDallas, Texas, 75390, United States
-
Local Institution - 0031
ACTIVE_NOT_RECRUITINGBrisbane, Queensland, 4029, Australia
-
Local Institution - 0032
ACTIVE_NOT_RECRUITINGVancouver, British Columbia, V5Z 4E6, Canada
-
The West Clinic, PLLC dba West Cancer Center
RECRUITINGGermantown, Tennessee, 38138, United States
Contact Phone: •••-•••-••••